Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Cytokine. 2012 Feb 21;58(2):245–252. doi: 10.1016/j.cyto.2012.01.012

Figure 1. Treatment of human BMSC and HOB with Melphalan decreases Interleukin-6 protein.

Figure 1

BMSC (A,C) and HOB (B,D) cells were seeded into a 96 well plate in triplicate and left untreated or were treated with melphalan [50 μg/ml] in media for 24 hours. After 24 hours, the media was replaced and supernatants (A,B) or cell lysates in RIPA buffer (C,D) were collected at the time points above. An Interleukin-6 ELISA was performed to quantitate changes in the levels of IL-6 protein secreted following chemotherapy. While IL-6 protein levels in supernatants were consistently reduced, no accumulation of intracellular IL-6 was observed to suggest deregulated secretion. One-way ANOVA and Tukey post hoc tests were used for analysis of data summarized in graphs A and B. One-way ANOVA and Tukey post hoc and Student’s t-tests were used for data presented in graphs C and D. For data included in graph C, Student’s t-test was used for the 24 and 48 hour time points and for data shown in graph D, Student’s t-test was used for the 6, 8, 24 and 48 hour time points, as these points fell out of the range that could be tested appropriately in the ANOVA (* represents p<0.05).